Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer

Objective To investigate the predictive and guiding significance of peripheral blood biomarkers on the therapeutic effects of PD-1/PD-L1 inhibitor treatment on lung cancer patients. Methods We collected the data of 200 lung cancer patients treated with PD-1/PD-L1 inhibitors treatment, including clin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	KE Ping, JIANG Bo, HE Wenjie, TU Changling, NIE Jun, ZHU Ying, YIN Qing, SUN Ruizhu
Formato:	article
Lenguaje:	ZH
Publicado:	Magazine House of Cancer Research on Prevention and Treatment 2021
Materias:	lung cancer immune checkpoint inhibitors peripheral blood markers efficacy survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a7202bbdc4e14e0baee2aadfa41fd34c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7202bbdc4e14e0baee2aadfa41fd34c
record_format	dspace
spelling	oai:doaj.org-article:a7202bbdc4e14e0baee2aadfa41fd34c2021-12-03T09:25:17ZCorrelation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer1000-857810.3971/j.issn.1000-8578.2021.21.0357https://doaj.org/article/a7202bbdc4e14e0baee2aadfa41fd34c2021-11-01T00:00:00Zhttp://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0357https://doaj.org/toc/1000-8578Objective To investigate the predictive and guiding significance of peripheral blood biomarkers on the therapeutic effects of PD-1/PD-L1 inhibitor treatment on lung cancer patients. Methods We collected the data of 200 lung cancer patients treated with PD-1/PD-L1 inhibitors treatment, including clinical indicators, peripheral blood indicators, efficacy indicators and survival indicators. Results The DCR of patients with non-hepatic metastasis, immune combined chemotherapy, NLR≤2.81 and LDH≤202.5 u/L was higher (P < 0.05). The AUC value of NLR combined with LDH predicting DCR was 0.698 (P < 0.05). Univariate analysis showed that non-hepatic metastasis, first-line immunotherapy, immunotherapy combined with chemotherapy and LDH≤202.5 u/L were related to PFS (P < 0.05). Multivariate analysis showed that the patients with non-hepatic metastasis and LDH≤202.5 u/L had longer PFS (P < 0.05). The significant decrease of NLR and LDH after two cycles of immunotherapy indicated the effectiveness of immunotherapy (P < 0.05). Conclusion NLR≤2.81, LDH≤202.5 u/L, non-hepatic metastasis and immunotherapy combined chemotherapy are positively correlated with immunotherapy efficacy. Non-hepatic metastasis and LDH≤202.5 u/L are independent prognostic factors of the patients treated with immunotherapy. The changes of peripheral blood NLR and LDH are related to the efficacy of PD-1/PD-L1 inhibitors treatment.KE PingJIANG BoHE WenjieTU ChanglingNIE JunZHU YingYIN QingSUN RuizhuMagazine House of Cancer Research on Prevention and Treatmentarticlelung cancerimmune checkpoint inhibitorsperipheral blood markersefficacysurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHZhongliu Fangzhi Yanjiu, Vol 48, Iss 11, Pp 1006-1011 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	lung cancer immune checkpoint inhibitors peripheral blood markers efficacy survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung cancer immune checkpoint inhibitors peripheral blood markers efficacy survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 KE Ping JIANG Bo HE Wenjie TU Changling NIE Jun ZHU Ying YIN Qing SUN Ruizhu Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
description	Objective To investigate the predictive and guiding significance of peripheral blood biomarkers on the therapeutic effects of PD-1/PD-L1 inhibitor treatment on lung cancer patients. Methods We collected the data of 200 lung cancer patients treated with PD-1/PD-L1 inhibitors treatment, including clinical indicators, peripheral blood indicators, efficacy indicators and survival indicators. Results The DCR of patients with non-hepatic metastasis, immune combined chemotherapy, NLR≤2.81 and LDH≤202.5 u/L was higher (P < 0.05). The AUC value of NLR combined with LDH predicting DCR was 0.698 (P < 0.05). Univariate analysis showed that non-hepatic metastasis, first-line immunotherapy, immunotherapy combined with chemotherapy and LDH≤202.5 u/L were related to PFS (P < 0.05). Multivariate analysis showed that the patients with non-hepatic metastasis and LDH≤202.5 u/L had longer PFS (P < 0.05). The significant decrease of NLR and LDH after two cycles of immunotherapy indicated the effectiveness of immunotherapy (P < 0.05). Conclusion NLR≤2.81, LDH≤202.5 u/L, non-hepatic metastasis and immunotherapy combined chemotherapy are positively correlated with immunotherapy efficacy. Non-hepatic metastasis and LDH≤202.5 u/L are independent prognostic factors of the patients treated with immunotherapy. The changes of peripheral blood NLR and LDH are related to the efficacy of PD-1/PD-L1 inhibitors treatment.
format	article
author	KE Ping JIANG Bo HE Wenjie TU Changling NIE Jun ZHU Ying YIN Qing SUN Ruizhu
author_facet	KE Ping JIANG Bo HE Wenjie TU Changling NIE Jun ZHU Ying YIN Qing SUN Ruizhu
author_sort	KE Ping
title	Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
title_short	Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
title_full	Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
title_fullStr	Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
title_full_unstemmed	Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
title_sort	correlation between peripheral blood biomarkers and efficacy of pd-1/pd-l1 inhibitors treatment on lung cancer
publisher	Magazine House of Cancer Research on Prevention and Treatment
publishDate	2021
url	https://doaj.org/article/a7202bbdc4e14e0baee2aadfa41fd34c
work_keys_str_mv	AT keping correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer AT jiangbo correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer AT hewenjie correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer AT tuchangling correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer AT niejun correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer AT zhuying correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer AT yinqing correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer AT sunruizhu correlationbetweenperipheralbloodbiomarkersandefficacyofpd1pdl1inhibitorstreatmentonlungcancer
_version_	1718373347836821504

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer

Ejemplares similares